Shanlee M Davis1,2, Najiba Lahlou3,4, Matthew Cox-Martin5, Karen Kowal6,7, Philip S Zeitler1,2, Judith L Ross6,7. 1. Department of Pediatrics, University of Colorado School of Medicine, Aurora, Colorado. 2. Section of Pediatric Endocrinology, Children's Hospital Colorado, Aurora, Colorado. 3. Hopital Cochin, Laboratoire d'Hormonologie, Paris, France. 4. BPR Clinical Laboratories, Pannes, France. 5. Adult and Child Consortium for Health Outcomes Research and Delivery Science (ACCORDS) Program, University of Colorado School of Medicine, Aurora, Colorado. 6. Department of Pediatrics, Thomas Jefferson University, Philadelphia, Pennsylvania. 7. A.I. DuPont Hospital for Children, Wilmington, Delaware.
Abstract
Context: Klinefelter syndrome (KS) is a common genetic condition in which males have an extra X chromosome. KS is associated with testosterone deficiency, neurodevelopmental delays, and cardiometabolic disorders. There has been recent interest in prepubertal androgen treatment; however, the effects on puberty and gonadal function are unknown. Objective: To compare onset of puberty and testicular function in prepubertal boys treated with 2 years of oxandrolone (Ox) vs placebo (Pl). Design: Double-blind, randomized, controlled trial. Setting: Single tertiary care referral center. Participants: Eighty prepubertal boys with KS; mean age: 8.0 ± 2.2 years (range: 4 to 12). Interventions: Ox 0.05 mg/kg vs identical-appearing Pl capsule given for 2 years. Outcome Measures: Onset of gonadarche (testicular volume ≥4 mL) and onset of pubarche (Tanner 2 pubic hair); change in testicular hormone concentrations. Results: Ox-treated group had 20.5 times higher odds of reaching gonadarche (OR 95% CI: 6.5, 77.8) and 28.1 times higher odds of reaching pubarche (OR 95% CI: 8.8, 110.4) during the 2-year study period after adjusting for baseline age. Gonadarche and pubarche both occurred at a younger age in the Ox group (gonadarche: 9.8 ± 1.5 vs 12.1 ± 1.0 years, P < 0.001; pubarche: 10.2 ± 1.1 vs 11.6 ± 1.3 years, P = 0.02). Serum concentrations of testicular hormones and gonadotropins were not different between groups. Conclusions: Two years of Ox treatment in prepubertal boys with KS results in an increased risk of early gonadarche, on average 2 years earlier than in Pl-treated boys. Ox did not affect serum concentrations of testicular hormones.
RCT Entities:
Context:Klinefelter syndrome (KS) is a common genetic condition in which males have an extra X chromosome. KS is associated with testosterone deficiency, neurodevelopmental delays, and cardiometabolic disorders. There has been recent interest in prepubertal androgen treatment; however, the effects on puberty and gonadal function are unknown. Objective: To compare onset of puberty and testicular function in prepubertal boys treated with 2 years of oxandrolone (Ox) vs placebo (Pl). Design: Double-blind, randomized, controlled trial. Setting: Single tertiary care referral center. Participants: Eighty prepubertal boys with KS; mean age: 8.0 ± 2.2 years (range: 4 to 12). Interventions: Ox 0.05 mg/kg vs identical-appearing Pl capsule given for 2 years. Outcome Measures: Onset of gonadarche (testicular volume ≥4 mL) and onset of pubarche (Tanner 2 pubic hair); change in testicular hormone concentrations. Results: Ox-treated group had 20.5 times higher odds of reaching gonadarche (OR 95% CI: 6.5, 77.8) and 28.1 times higher odds of reaching pubarche (OR 95% CI: 8.8, 110.4) during the 2-year study period after adjusting for baseline age. Gonadarche and pubarche both occurred at a younger age in the Ox group (gonadarche: 9.8 ± 1.5 vs 12.1 ± 1.0 years, P < 0.001; pubarche: 10.2 ± 1.1 vs 11.6 ± 1.3 years, P = 0.02). Serum concentrations of testicular hormones and gonadotropins were not different between groups. Conclusions: Two years of Ox treatment in prepubertal boys with KS results in an increased risk of early gonadarche, on average 2 years earlier than in Pl-treated boys. Ox did not affect serum concentrations of testicular hormones.
Authors: Carole A Samango-Sprouse; Teresa Sadeghin; Francine L Mitchell; Teresa Dixon; Emily Stapleton; Madison Kingery; Andrea L Gropman Journal: Am J Med Genet A Date: 2013-01-23 Impact factor: 2.802
Authors: O H Pescovitz; F Comite; F Cassorla; A J Dwyer; M A Poth; M A Sperling; K Hench; A McNemar; M Skerda; D L Loriaux Journal: J Clin Endocrinol Metab Date: 1984-05 Impact factor: 5.958
Authors: Tais F Galvao; Marcus T Silva; Ivan R Zimmermann; Kathiaja M Souza; Silvia S Martins; Mauricio G Pereira Journal: J Affect Disord Date: 2013-11-08 Impact factor: 4.839
Authors: Simon Chang; Anne Skakkebaek; Shanlee M Davis; Claus H Gravholt Journal: Am J Med Genet C Semin Med Genet Date: 2020-06-04 Impact factor: 3.908
Authors: Jaroslav Galba; Juraj Piešťanský; Andrej Kováč; Dominika Olešová; Ondrej Cehlár; Martin Kertys; Petr Kozlík; Petra Chaľová; Barbora Tirčová; Kristián Slíž; Peter Mikuš Journal: Molecules Date: 2021-01-18 Impact factor: 4.411